ArticleFrontiers in aging2025
Chinese validation of "subjective motoric cognitive risk syndrome" screening tool in patients with coronary artery disease using Rasch analysis.
Article in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Subjective motoric cognitive risk syndrome (MCR-S) is a well-established screening tool that has been validated for objective motoric cognitive risk syndrome (MCR-O) and predicted risk of incident dementia. MCR is associated with cardiovascular factors and coronary artery disease (CAD). MCR-S is crucial for remote cognitive screening but has only been validated in community settings so far. Our study aimed to validate a Chinese version of the MCR-S in CAD patients. Method: The Chinese version of the MCR-S was obtained through a standardized forward-backward translation and cultural adaptation. 338 CAD patients were recruited. Traditional analysis based on classical test theory and Rasch analysis based on latent trait theory were performed on the MCR-S for validation. Receiver operating characteristic analysis was applied to determine the discriminative ability of MCR-S for the MCR-O in CAD patients. Results: The MCR-S met the unidimensionality, lack of local dependency or disordered thresholds, and good fit value for each item of the Rasch model, the item-person map shows that the item's estimate of capacity is appropriate. MCR-S has good content validity, criterion-related validity, and test-retest reliability. An optimal cut-score of 4.6 on the MCR-S score was determined to have good sensitivity (79.2%) and specificity (71.3%) for MCR-O in CAD patients. Conclusion: The Chinese version of MCR-S meets the requirements of the Rasch model and has good validity in CAD patients. The validated MCR-S cutoff can support long-term monitoring and early intervention for CAD patients at risk of MCR-O.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.